Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
出版信息
Technol Eval Cent Assess Program Exec Summ. 2013 Feb;27(5):1-4.
PMID:23589929
Abstract
摘要
相似文献
1
Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
Technol Eval Cent Assess Program Exec Summ. 2013 Feb;27(5):1-4.
2
Brain amyloid imaging--FDA approval of florbetapir F18 injection.
N Engl J Med. 2012 Sep 6;367(10):885-7. doi: 10.1056/NEJMp1208061.
3
Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
Arch Neurol. 2008 Oct;65(10):1281-3. doi: 10.1001/archneur.65.10.1281.
4
Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Alzheimers Dement. 2014 Oct;10(5 Suppl):S395-9. doi: 10.1016/j.jalz.2013.09.007. Epub 2014 Jan 10.
5
[Amyloid-plaque imaging of the brain using PET].
Ned Tijdschr Geneeskd. 2011;155:A2981.
6
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
Arch Neurol. 2008 Oct;65(10):1304-9. doi: 10.1001/archneur.65.10.noc80013. Epub 2008 Aug 11.
7
An imaging agent for amyloid.
Med Lett Drugs Ther. 2012 Jul 9;54(1394):54-5.
8
Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
J Mol Neurosci. 2004;24(1):55-62. doi: 10.1385/JMN:24:1:055.
9
Florbetapir F 18 for brain imaging of β-amyloid plaques.
Drugs Today (Barc). 2013 Mar;49(3):181-93. doi: 10.1358/dot.2013.49.3.1937428.
10
Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
J Alzheimers Dis. 2013;33 Suppl 1:S349-59. doi: 10.3233/JAD-2012-129034.
Zotero 插件